Articles tagged with Weight Loss
A study on apple cider vinegar's effectiveness in weight loss was retracted by BMJ Group due to significant methodological flaws, including implausible statistical values and inadequate reporting. The retraction was prompted by concerns raised by statisticians and experts who were unable to replicate the results.
A new study published in JAMA Network Open shows that regular phone support after losing weight is crucial for maintaining weight loss. Participants who received monthly phone calls maintained an average of 8% weight loss from their starting weight, with about 60% keeping off at least 5% of their initial weight.
A Georgia State University researcher has received a $25,000 grant to develop mechanisms for treating obesity and related metabolic dysfunctions. The goal is to identify therapeutic candidates with strong clinical translation capabilities.
The SURPASS-PEDS trial shows that tirzepatide significantly improves HbA1c levels, BMI, and fasting glucose in children aged 10-17 years with type 2 diabetes. The study demonstrates sustained improvements over a year-long period, making it a potential safe and efficacious treatment option for youth-onset type 2 diabetes.
Mayo Clinic researchers developed a genetic test that can predict how people will respond to weight loss medications. The test estimates an individual's calories to satiation, linking it to treatment success and providing personalized estimates of expected satiation threshold.
A new study uses three wearable sensors to track eating behavior and identifies five distinct patterns, including late-night snacking and stress binging. The findings lay the groundwork for personalized interventions to help individuals overcome unconscious habits that drive overeating.
New research finds that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of death and major cardiovascular events in psoriasis patients. GLP-1RAs also show promise in reducing alcohol and substance abuse, with a 65% lower risk of alcohol abuse.
A study of 92 individuals with type 2 diabetes found that those who overeat due to emotional reasons are less likely to lose clinically significant weight while taking GLP-1 receptor agonists. In contrast, individuals who eat in response to external stimuli tend to respond well to the therapy.
Metabolic bariatric surgery shows promise as a cost-effective weight loss option for class II and III obesity patients. The study found bariatric surgery resulted in greater weight loss compared to GLP-1 receptor agonists.
A phase 3 trial of once-daily orforglipron found substantial weight loss in people with obesity but not type 2 diabetes. The medication improved cardiometabolic levels and was associated with significant reductions in body weight, waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol.
A randomised trial found that regular exercise reduced inflammation and improved endothelial function, leading to lower risk of heart attack and strokes. Exercise maintained weight loss without GLP-1 receptor agonist liraglutide.
Research suggests that semaglutide, a weight loss medication, decreases intrusive thoughts about food and improves mental health in individuals with obesity. The study found that 81% of participants experienced less food noise after taking semaglutide for at least four months.
A study of individuals taking Ozempic, Wegovy, or Mounjaro found that 21.3% reported food tasting sweeter, while 22.6% said it tasted saltier than before. These changes were linked to reduced appetite and weight loss in all groups, with participants who experienced increased sweetness being twice as likely to report increased satiety.
A national study found that half of adults without diabetes who started taking semaglutide for weight loss discontinued treatment within a year. The most common factors influencing discontinuation were age, with younger users more likely to stop, as well as high costs and higher predisposition to adverse effects.
Researchers at Penn State found that weight fluctuations and changes can lead to faster cognitive decline in older adults. The study analyzed data from 4,304 participants and showed that those with greater variability in weight experienced more rapid cognitive declines.
A cohort study shows bariatric surgery significantly lowers major metabolic comorbidity risk compared to medical weight management. The procedure is deemed a durable approach for obesity-related risk mitigation.
Despite the NHS roll-out of Mounjaro officially starting in June 2025, less than half of England has access to the weight-loss jab. An estimated 3.4 million people could benefit from tirzepatide, but only 18 out of 42 commissioning bodies have started prescribing it, leaving many patients without treatment.
A synthetic molecule called Pep19 has been shown to reduce visceral fat and improve sleep quality in overweight adults, with no side effects observed. The study involved 24 volunteers who took either a placebo or Pep19 in capsules, and found a 17% reduction in visceral fat and improved sleep quality in those who received the molecule.
A cohort study found that GLP-1 receptor agonist prescriptions are associated with a reduced risk of uveitis compared to controls. The findings suggest potential anti-inflammatory benefits beyond glycemic control, warranting further investigation into their role in ocular inflammatory diseases.
A retrospective cohort study found that approximately 1 in 10 US adults undergoing bariatric surgery initiated glucagon-like peptide-1 receptor agonists. The use of these medications was more common among women and individuals with larger body mass index regain after surgery.
A new study found that excessive visceral fat is linked to faster ageing of the heart, with a genetic predisposition to female-type fat in women potentially slowing heart ageing. Researchers also discovered that artificial intelligence analysis of images revealed signs of organ ageing, including tissue stiffness and inflammation.
A telephone-based weight loss intervention significantly reduced weight in breast cancer patients with overweight and obesity. The study suggests that this intervention may improve disease outcomes, warranting further investigation in future trials.
Researchers have developed edible microbeads that, when consumed, bind to fats in the gastrointestinal tract, potentially providing a safer and more accessible alternative to surgery or pharmaceuticals. The microbeads are made from green tea polyphenols, vitamin E, and seaweed, and show promise for weight loss in rats fed high-fat diets.
A new imaging approach allows researchers to visualize how dual-acting diabetes and obesity drugs like tirzepatide interact with cells in the pancreas and brain. The tool, called daLUXendins, provides insight into the metabolic effects triggered by these drugs, which stimulate both GLP-1R and GIPR receptors.
A new study found that adolescents with higher blood levels of per- and polyfluoroalkyl substances (PFAS) prior to bariatric surgery regained more weight and had greater increases in waist circumference up to five years after surgery. Researchers believe PFAS exposure disrupts endocrine and metabolic processes, leading to weight regain.
A systematic review and meta-analysis found that weight loss interventions before IVF increased unassisted pregnancy rates, while the effect on live births was unclear. Weight loss interventions studied included low-energy diets, exercise programs, and pharmacotherapy.
Initiation of semaglutide in adults leads to reductions in weight and cardiovascular risk factors, while increasing health care expenditures. These findings suggest potential clinical benefits, highlighting the need for long-term evaluation of semaglutide's economic impact.
Researchers found that Ozempic-induced weight loss decreased lean mass by 10% in mice, with most of the lost weight coming from non-skeletal tissues. While some skeletal muscles did shrink, others stayed the same size, and strength was affected for some but not all muscles.
Nearly 17 million teens and young adults are eligible for GLP-1RA therapy, but one in five is uninsured and nearly a third lack healthcare access, hindering treatment of cardio-kidney-metabolic diseases.
A new therapy, regulation of cues combined with behavioral weight loss (ROC+BWL), was found to be more effective than standard cognitive behavioral therapy in reducing binge eating among veterans. The benefits were sustained even six months after treatment ended.
In a randomized clinical trial, oral semaglutide significantly reduced body weight in East Asian adults with overweight or obesity, regardless of type 2 diabetes presence. The study's safety profile is consistent with glucagon-like peptide-1 receptor agonists.
Researchers from NUS have tracked changes in gene expression and splicing patterns in skeletal muscle after a 16-week lifestyle intervention program involving supervised exercise and dietary changes. The study found that participants lost weight and improved insulin sensitivity, with specific genes showing evidence of G x L interaction.
A new genetic test can predict adulthood obesity in early childhood, allowing for targeted preventative strategies. The test was developed using data from over five million people and found to be twice as effective as previous tests at predicting obesity risk.
A meta-analysis published in BMC Medicine found that patients prescribed anti-obesity medications may experience a significant weight gain after stopping their prescription. The study analyzed data from 11 randomised trials and suggests that six approved anti-obesity medications are associated with weight regain after treatment cessation.
A new study identified neurobeachin as a genetic predictor of weight loss response to GLP-1RAs. The findings have the potential to advance obesity care and provide more effective, personalized treatment options.
A survey of 2,000 single U.S. adults found that GLP-1 weight-loss drugs are affecting people's sex lives and dating experiences, with men reporting increased libido and confidence. Women, on the other hand, are more likely to report low libido and decreased sexual function.
A new study found that anti-obesity medications can normalize testosterone levels in men with obesity or type 2 diabetes. This positive effect on reproductive health was observed after a 10% weight loss, with total and free testosterone levels increasing by 24%.
A new study found that intermittent energy restriction significantly improved fasting blood glucose and triglycerides, while also increasing insulin sensitivity. The IER group showed the greatest advantages in reducing these markers compared to time-restricted eating and continuous energy restriction groups.
A recent study of 1,543 males aged 15 to 35 found that those who used prescription weight loss medications reported significantly higher levels of disordered eating behaviors and attitudes. The study suggests that boys and men may face unique pressures or vulnerabilities related to body image and weight control, highlighting the need f...
A recent study published in Nature reveals that weight loss triggers the breakdown and recycling of fats called lipids, potentially leading to improved health outcomes. Weight loss also clears out senescent cells, which are ageing and damaged cells that accumulate in tissues, reducing inflammation and scarring.
A study of 679 patients found that longer GLP-1RA treatment, not having diabetes, and higher body fat were associated with better weight reduction. Higher muscle mass and metabolic rate also contributed to successful weight loss in patients with overweight or obesity.
A national survey of 1,000 American adults found that stress (43%) and lack of sleep (39%) are major contributors to a short attention span. The study also identified digital devices as a significant factor, with 35% of respondents citing it as a contributing factor.
Researchers have discovered how FGF19, produced in the intestine, acts on specific regions of the brain to regulate energy expenditure. The hormone stimulates thermogenic adipocyte activity, leading to increased fat burning and improved blood glucose levels in obese animals.
Recent research reveals that adipose-derived stem cells from obese individuals do not fully recover their anti-inflammatory capacity even two to three years after significant weight loss. The study, published in Stem Cells International, used bariatric surgery as a model to investigate the impact of weight loss on these stem cells.
Experts say that focusing on weight loss alone for obesity may not provide sustained long-term results and can contribute to societal weight bias. A patient-centered approach prioritizing health over weight is recommended.
The experimental drug SANA has been shown to prevent fat accumulation, treat existing obesity, and reverse associated metabolic disorders. In animal tests, it activated thermogenesis through an unconventional mechanism, targeting adipose tissue cells to produce heat without involving the UCP1 protein.
A new potential drug treatment has shown promising results in reducing blood sugar levels and increasing fat burning in people with type 2 diabetes and obesity. The treatment activates metabolism in skeletal muscle, promoting healthy weight loss and preserving muscle mass, a key factor in metabolic health.
Early-phase clinical trials of a new weight management medication amycretin have confirmed its safety and tolerability. The medication targets two specific receptors to help control blood sugar and appetite, showing promise in treating overweight, obesity, and type 2 diabetes.
The American College of Cardiology has issued a Concise Clinical Guidance document to inform clinicians about medication for weight management in patients with cardiovascular benefit. Modern obesity medications, such as semaglutide and tirzepatide, have been proven effective in reducing overall cardiovascular disease risk.
A new study found that weighted vests and resistance training did not prevent bone loss in older adults undergoing intentional weight loss. The researchers call for alternative strategies to protect skeletal health in aging populations with obesity.
A new study found that self-esteem scores doubled within one year of weight-loss surgery, with the highest increases seen among those who lost the most weight. The study also highlighted the importance of understanding and addressing weight stigma in obesity treatment.
A University of Oxford study found that an intensive low-energy diet programme significantly improved eating disorder symptoms in people with type 2 diabetes and excess weight at risk of developing eating disorders. The programme showed benefits persisting six months after completion.
Researchers at Tufts University have designed a new compound that incorporates structural elements of four hormones - GLP-1, GIP, glucagon, and PYY - to create a single weight loss drug. This chimera peptide aims to address the drawbacks of current weight loss drugs, such as nausea and limited efficacy.
A Cleveland Clinic study found that patients taking injectable GLP-1 medications for obesity lost an average of 3.6% body weight, significantly lower than the 11.9% seen in non-discontinuers. Treatment discontinuation negatively impacted blood sugar control in those with prediabetes.
A new study found that nearly one-third of individuals adopting healthy diets didn't lose weight but still experienced significant improvements in cardiometabolic markers, including increased HDL cholesterol and reduced visceral fat. The research suggests a healthy diet can have benefits beyond weight loss.
Researchers identified biomarkers like uric acid and bile acids as critical regulators of arterial stiffness and inflammation in adolescents with obesity. These findings provide new avenues for early intervention to prevent the progression of vascular stiffness and cardiovascular disease.
New research shows that weight stigma and not weight itself have the biggest impact on mental health and healthy behaviors in patients after weight-loss surgery. This reduction in weight stigma is linked to improvements in both mental and physical health, including lower levels of anxiety and depression.
A Virginia Tech professor has received a proof-of-concept grant to further develop a chemical compound that could help promote weight loss by increasing mitochondrial activity. The compound, named BAM15, shows promise in preclinical studies without affecting food intake or muscle mass.
Researchers at University of Gothenburg identified a group of nerve cells controlling semaglutide's appetite-suppressing effects without causing nausea. The discovery may lead to improved treatments for obesity and type 2 diabetes.
This novel treatment approach yields better weight loss maintenance and cardiovascular risk outcomes compared to standard-of-care treatment. Patient-delivered lifestyle intervention combined with peer support significantly improves weight loss and reduces cardiovascular risk.